DEVINCENZO JP, AITKEN J, HARRISON L; Interscience Conference on Antimicrobial Agents and Chemotherapy (41st : 2001 : Chicago, Ill.).
Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 2001 Dec 16-19; 41: abstract no. G-1828.
University of Tennessee and CFMRC, Memphis, TN
BACKGROUND: Monthly injections of a monoclonal antibody (MAb) directed at the RSV fusion protein (palivizumab (pali)) lowers the risk and duration of RSV hospitalization in premature (2mo prior to hospitalization. Nasal washes were collected in a standardized fashion and were cultured within 3 hr in parallel with an RSV standard in a Hep-2 cell plaque assay. RESULTS: Mean (median) RSV loads in the pali and non pali groups were 3.12 (2.81) vs 5.20 (4.81) log PFU/ml. Loads were significantly different between groups (Mann-Whitney P=0.0078) and remained significant when culture-negative patients were discarded (P<0.05). [figure: see text] As expected, pali recipients were more premature (median gestational age 27 vs 33 wks P<0.05). No significant differences in admission weight or age were seen. CONCLUSION: prophylactic palivizumab results in reduced nasal viral replication in premature infants hospitalized with RSV infection.
Publication Types:
Keywords:
- Antibodies, Monoclonal
- Gestational Age
- Hemagglutination Tests
- Hospitalization
- Humans
- Immunoglobulins, Intravenous
- Infant
- Infant, Newborn
- Infant, Premature
- Infant, Premature, Diseases
- Plaque Assay
- Prospective Studies
- Recombinant Fusion Proteins
- Respiratory Syncytial Virus Infections
- Respiratory Syncytial Viruses
- palivizumab
Other ID:
UI: 102270169
From Meeting Abstracts